Other Events ·
Ultragenyx settles DOJOLVI patent litigation with Navinta, granting generic license starting Jan. 1, 2033
RAREUltragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., Baylor Research Institute, and Navinta LLC entered into a settlement agreement resolving patent litigation concerning the Company's drug DOJOLVI (triheptanoin). The dispute arose from Navinta's Abbreviated New Drug Application to market a generic version of the product. Under the terms, Ultragenyx grants Navinta a non-exclusive, royalty-free license to sell its generic DOJOLVI beginning January 1, 2033, potentially extending to July 1, 2033 if pediatric exclusivity is granted. Other pending litigation against different ANDA filers remains active. The company operates in the biopharmaceutical industry, developing treatments for rare genetic diseases.